MESA VERDE

Interim results of a Phase 1b trial of cirmtuz umab and paclitaxel in locally advanced/unresectable or metastatic HER2-negative breast...

- First quarter of full complement of 60 sales representatives further expanding the reach of XENLETA® (lefamulin) and SIVEXTRO®...

Presentations highlight the pathogenic role of the CD6-ALCAM pathway, the immunologic impact of modulating this pathway with itolizumab,...

MatriSys Bioscience, a company harnessing beneficial bacteria to treat inflammatory skin diseases, today announced the hiring of Joyce...

ALASTIN Skincare®, Inc., a specialty aesthetics company dedicated to developing and marketing innovative, clinically-tested...